RNLX · Renalytix PLC - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 | Q1 '23 | FY 2023 | Q4 '22 | FY 2022 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $522.0K | $709.0K | $535.0K | $459.0K | - | - | $724.0K | - | $1.19M | - |
| Cost of Revenue | $422.0K | $480.0K | $601.0K | $502.0K | - | - | $603.0K | - | $711.0K | - |
| Gross Profit | $100.0K | $229.0K | ($66.0K) | ($43.0K) | - | - | $121.0K | - | $481.0K | - |
| R&D | $921.0K | $3.23M | $2.22M | $2.79M | - | - | $3.94M | - | $3.33M | - |
| SG&A | $3.27M | $5.34M | $3.85M | $6.06M | - | - | $7.09M | - | $6.81M | - |
| Total Operating Expenses | $4.19M | $8.87M | $6.49M | $8.85M | - | - | $11.04M | - | $10.13M | - |
| D&A | $60.0K | $100.0K | $20.0K | $127.0K | - | - | $100.0K | - | $130.0K | - |
| Operating Income | ($4.09M) | ($8.64M) | ($6.55M) | ($8.89M) | - | - | ($10.92M) | - | ($9.65M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $2.0K | $4.0K | $0 | $0 | - | - | ($1.0K) | - | $0 | - |
| Net Income | ($4.73M) | ($8.48M) | ($7.74M) | ($10.15M) | - | - | ($12.11M) | - | ($10.44M) | - |
| EPS - Basic | ($0.04) | ($0.09) | ($0.08) | ($0.11) | - | - | ($0.14) | - | ($0.14) | - |
| EPS - Diluted | ($0.04) | ($0.09) | ($0.08) | ($0.11) | - | - | ($0.14) | - | ($0.14) | - |
Balance Sheet
| Line item | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 | Q1 '23 | FY 2023 | Q4 '22 | FY 2022 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $909.0K | $4.68M | $4.70M | $13.89M | $24.68M | $33.03M | - | $23.82M | - | $31.04M |
| Accounts Receivable | $902.0K | $722.0K | $554.0K | $1.01M | $776.0K | $747.0K | - | $820.0K | - | $1.22M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | $1.75M | - | $2.21M | - | $1.89M |
| Current Assets | $2.88M | $6.12M | $6.34M | $16.47M | $26.88M | $35.73M | - | $26.60M | - | $34.43M |
| Total Assets | $4.79M | $7.97M | $8.77M | $19.54M | $30.63M | $39.80M | - | $30.66M | - | $38.71M |
| Current Liabilities | $12.01M | $11.49M | $14.99M | $15.17M | $16.14M | $14.68M | - | $14.29M | - | $13.33M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $16.11M | $15.83M | $19.88M | $21.03M | $23.66M | $21.70M | - | $21.77M | - | $19.87M |
| Stockholders' Equity | ($11.32M) | ($7.85M) | ($11.11M) | ($1.49M) | $6.97M | $18.10M | - | $8.88M | - | $18.84M |
| Retained Earnings | ($216.51M) | ($211.78M) | ($204.71M) | ($188.48M) | ($178.32M) | ($167.22M) | - | ($155.12M) | - | ($144.67M) |
Cash Flow
| Line item | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 | Q1 '23 | FY 2023 | Q4 '22 | FY 2022 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($3.84M) | - | - | ($9.50M) | - | - | - | - | ($7.12M) | - |
| Investing Cash Flow | $23.0K | - | - | $0 | - | - | - | - | $0 | - |
| Financing Cash Flow | $0 | - | - | ($1.06M) | - | - | - | - | ($944.0K) | - |
| CapEx | - | - | - | - | - | - | - | - | $0 | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | ($7.12M) | - |
Ratios
| Metric | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 | Q1 '23 | FY 2023 | Q4 '22 | FY 2022 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 19.2% | 32.3% | -12.3% | -9.4% | - | - | 16.7% | - | 40.4% | - |
| Operating margin | -784.1% | -1218.8% | -1224.9% | -1936.6% | - | - | -1507.9% | - | -809.4% | - |
| EBITDA margin | -772.6% | -1204.7% | -1221.1% | -1908.9% | - | - | -1494.1% | - | -798.5% | - |
| Net margin | -905.7% | -1196.8% | -1447.3% | -2212.2% | - | - | -1672.1% | - | -876.2% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | -597.2% | - |
| FCF / Net income | - | - | - | - | - | - | - | - | 0.68 | - |
| R&D / Revenue | 176.4% | 454.9% | 414.2% | 607.2% | - | - | 544.6% | - | 279.0% | - |
| SG&A / Revenue | 626.6% | 753.0% | 720.4% | 1320.0% | - | - | 980.0% | - | 571.3% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -98.6% | -106.4% | -88.3% | -52.0% | - | - | - | - | - | - |
| Return on equity | 41.8% | 108.0% | 69.7% | 681.0% | - | - | - | - | - | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.24 | 0.53 | 0.42 | 1.09 | 1.67 | 2.43 | - | 1.86 | - | 2.58 |
| Quick ratio | 0.24 | 0.53 | 0.42 | 1.09 | 1.67 | 2.43 | - | 1.86 | - | 2.58 |
| Cash ratio | 0.08 | 0.41 | 0.31 | 0.92 | 1.53 | 2.25 | - | 1.67 | - | 2.33 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | -0.42 | -1.02 | -0.79 | -13.11 | 4.40 | 2.20 | - | 3.45 | - | 2.05 |
| Liabilities / Assets | 3.36 | 1.99 | 2.27 | 1.08 | 0.77 | 0.55 | - | 0.71 | - | 0.51 |
| Efficiency | ||||||||||
| Asset turnover | 0.11 | 0.09 | 0.06 | 0.02 | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 631d | 372d | 378d | 806d | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 13.7% | - | - | - | - | - | -39.3% | - | 147.3% | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | 21.9% | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | -74.8% | - | 88.6% | - |
| Operating income growth (YoY) | 54.0% | - | - | - | - | - | -13.2% | - | 18.3% | - |
| Net income growth (YoY) | 53.4% | - | - | - | - | - | -15.9% | - | -3.3% | - |
| EPS growth (YoY) | 63.6% | - | - | - | - | - | 0.0% | - | 33.3% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | 33.6% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -659.2% | - | - | - | -77.2% | -38.5% | - | -80.6% | - | -68.6% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-06-30.
Product / service
$4.24M totalTesting Services Revenue$2.10M · 49.5%
Licensed Products$2.00M · 47.2%
Pharmaceutical Services Revenue$140.0K · 3.3%
Peer comparison
Same SIC group: Services-Medical Laboratories
Comparing Renalytix plc against the 5 most active filers in the same SIC group.